Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNV_Ent
- Development stage
- Preclinical
- Lead developer
- Immunethep
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
PNV_Ent is a peptide-based vaccine candidate developed by Immunethep that targets the extracellular form of bacterial glyceraldehyde-3-phosphate dehydrogenase (GAPDH). It is designed to provide broad-spectrum protection against infections caused by *Escherichia coli* and *Klebsiella pneumoniae*. The vaccine works by neutralizing extracellular bacterial GAPDH, a virulence factor used by these pathogens to evade the host immune system, while sparing human GAPDH. This neutralization allows the host's immune system to effectively recognize and clear the bacterial infection. In 2025, the program received funding from CARB-X to optimize its formulation for inducing robust and long-lasting immunity against these dangerous pathogens.
- Other names
- PNV-EntParagon Novel Vaccine Ent
02
Targets
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)
Beyond the preview
Go deeper on PNV_Ent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNV_Ent.